FDA drug class
Complement Inhibitors list
Every FDA-approved prescription drug the FDA NDC directory tags with the Complement Inhibitor [EPC] class, with brand names and DEA schedules.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
The FDA NDC directory lists 6 single-ingredient drugs in this class: avacincaptad pegol, eculizumab, pegcetacoplan, pozelimab, ravulizumab, zilucoplan.
Run it in Rivvi
Map Izervay and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Complement Inhibitors (6)
| Drug | Brand names | Type | NDC listings | DEA schedule |
|---|---|---|---|---|
| Avacincaptad pegol | Izervay | Single ingredient | 1 | Not controlled |
| Eculizumab | Soliris, Epysqli, Bkemv | Single ingredient | 3 | Not controlled |
| Pegcetacoplan | Syfovre, Empaveli | Single ingredient | 2 | Not controlled |
| Pozelimab | Veopoz | Single ingredient | 1 | Not controlled |
| Ravulizumab | Ultomiris | Single ingredient | 3 | Not controlled |
| Zilucoplan | Zilbrysq | Single ingredient | 3 | Not controlled |
FDA established pharmacologic class: Complement Inhibitor [EPC].
Questions
What drugs are Complement Inhibitors?
The FDA NDC directory lists 6 single-ingredient drugs in this class: avacincaptad pegol, eculizumab, pegcetacoplan, pozelimab, ravulizumab, zilucoplan.
Where does this list come from?
From the established pharmacologic class (EPC) field FDA publishes for each listing in the NDC directory. A drug is listed when most of its prescription listings carry the class.